June 26th, 2024: Study reveals GLP-1 drugs may cause bone density loss without exercise A recent study from the University of Copenhagen raises new concerns about GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, highlighting potential bone density loss
However, many individuals are reluctant to regain weight after experiencing significant weight loss, making discontinuation an unfavorable option
Most FDA-approved injections were pre-filled in 0.25 mg or 0.5 mg increments
Each of these treatments, through distinct pathways and mechanisms, provides pivotal options for patients dealing with the complexities of diabetes and weight management, reflecting the growing precision and personalization in medical care
They filled out questionnaires to provide demographic, clinical, and dietary information
When clinically appropriate, our St